In vivo study of novel nanocomposite for prostate cancer treatment

4th International Conference on Safe Production and Use of Nanomaterials

Silveira, C.P.^1 ; Paula, A.J.^2 ; Apolinário, L.M.^3 ; Fávaro, W.J.^3,4 ; Durán, N.^1,4,5

Chemistry Institute, Universidade Estadual de Campinas (UNICAMP), Campus Universitário Zeferino Vaz, s/n, Cidade Universitária, Campinas

CEP 13083-870, SP, Brazil^1

Department of Physics, Universidade Federal Do Ceará (UFC), Avenida da Universidade, Benfica, CEP 60020-181, CE, Fortaleza

2853, Brazil^2

Department of Environmental Engineering, Universidade Estadual Paulista (UNESP), Avenida Trs de Março, CEP 18087-180, SP, 511, Sorocaba, Brazil^3

Farmabrasilis R and D Division, Brazil^4

Nanobioss, Chemistry Institute, Universidade Estadual de Campinas (UNICAMP), Campus Universitário Zeferino Vaz, s/n, Cidade Universitária, Campinas

CEP 13083-870, SP, Brazil^5

关键词: Anticancer drug;    Cancer therapy;    Novel nanocomposites;    Phosphodiesterases;    Pluronic F-127;    Prostate cancers;    Side effect;    Tumor progressions;   

Others  :  https://iopscience.iop.org/article/10.1088/1742-6596/617/1/012001/pdf
DOI  :  10.1088/1742-6596/617/1/012001

来源: IOP

【 摘 要 】

Because of high occurrence of side effects of conventional anticancer drugs, new therapies have been widely studied, such as the use of non-usual molecules and the association with nanomaterials. In this context, sildenafil is a molecule that has been lately considered as a co-adjuvant in cancer therapy because it inhibits an enzyme with a potential role in tumor progression, phosphodiesterase-5. Taking into account the combination of nanoparticles and sildenafil, we produced systems based on mesoporoussilica nanoparticles, Pluronic F-127 and sildenafil as the main therapy for prostate cancer.